Dopamine receptor D3

The D₃ receptor belongs to the D2-like receptor subfamily, which also includes D2 and D4 receptors. It couples primarily to Gi/Go proteins, leading to inhibition of adenylyl cyclase and reduced intracellular cAMP levels.^[7]

The D₃ receptor displays the highest binding affinity for dopamine among dopamine receptor subtypes, making it a key regulator of tonic dopamine signaling.^[8]

D₃ receptors are primarily expressed in limbic brain regions such as the nucleus accumbens, islands of Calleja, and olfactory tubercle. Their distribution in phylogenetically older brain areas suggests an important role in emotion, motivation, and cognition.^[9]

Activation of the D₃ receptor regulates dopamine release and modulates neuronal excitability. Preclinical and clinical studies implicate it in:

• Parkinson's disease – D₃ agonists such as pramipexole and rotigotine show neuroprotective effects, reduce alpha-synuclein aggregation, and improve motor and non-motor symptoms.^[10]
• Neuropsychiatric disorders – Altered DRD3 signaling has been associated with schizophrenia, bipolar disorder, and major depression. Some D₃ ligands exert antidepressant-like effects in animal models.^[11]
• Addiction – D₃ receptors modulate reward pathways; antagonists such as SB-277011-A show promise in reducing drug-seeking behavior in preclinical models.^[12]

The DRD3 Ser9Gly polymorphism (rs6280) alters receptor binding characteristics and has been studied in relation to:

• Severity of depression in Parkinson's disease^[13]
• Impulse control disorders and behavioral addictions^[14]

D₃ ligands include:

• Agonists: pramipexole, ropinirole, rotigotine, 7-OH-DPAT, apomorphine
• Partial agonists: aripiprazole, brexpiprazole, cariprazine
• Antagonists: amisulpride, haloperidol, NGB-2904, SB-277011-A
• Allosteric modulators: SB269652

Many of these ligands are used clinically in Parkinson's disease or schizophrenia, while others remain experimental.

The D₃ receptor has been shown to interact with:

• CLIC6, an intracellular chloride channel protein^[15]
• EPB41L1, a cytoskeletal protein involved in membrane localization of GPCRs^[16]

• Therapeutic target – Due to its role in motor control, motivation, and reward, DRD3 is a therapeutic target for Parkinson's disease, schizophrenia, and substance use disorders.
• Drug design – High selectivity ligands for D₃ are actively pursued to minimize side effects associated with D₂ receptor blockade.
• Biomarker potential – Polymorphisms in DRD3 are under investigation as genetic biomarkers for treatment response and psychiatric vulnerability.

• Dopamine receptor D2
• Dopamine receptor D4
• Parkinson's disease
• Schizophrenia